Unexpected responses to EGFR inhibition in NSCLC

Unexpected responses to EGFR inhibition in NSCLC

The presence of activating mutations of the epidermal growth factor receptor (EGFR)-gene identifies a distinct and clinically relevant molecular subset of non-small-cell lung cancer. It is now well demonstrated that EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are superior to stand...

Full description

Bibliographic Details
Main Authors: Giulia M. Stella, Claudio Valizia, Michele Zorzetto, Simona Inghilleri, Adele Valentini, Roberto Dore, Sara Colombo, Francesco Valentino, Giulio Orlandoni, Patrizia Morbini
Format: Article
Language:English
Published: Elsevier 2015-01-01
Series:Respiratory Medicine Case Reports
Subjects:
Cancer genetics
Actionable markers
Targeted therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2213007115300113

Internet

http://www.sciencedirect.com/science/article/pii/S2213007115300113

Similar Items